Selank vs Semax: Comparing the Indexed Record
Selank and Semax appear together in search far more often than they appear together in published methodology. That gap is the useful part.
Compound profiles
Selank in the indexed record
The literature on Selank is a moderate body of work: 68 PubMed-indexed records, alongside 10 registered studies on ClinicalTrials.gov.
Journals represented in the current index include Behav Neurol, Bull Exp Biol Med, Dokl Biol Sci, spanning 2016–2026.
- Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions — J Am Acad Orthop Surg Glob Res Rev, 2026. PMID: 41490200
- Selank, a Peptide Analog of Tuftsin, Attenuates Aversive Signs of Morphine Withdrawal in Rats — Bull Exp Biol Med, 2022. PMID: 36322304
- Functional Connectomic Approach to Studying Selank and Semax Effects — Dokl Biol Sci, 2020. PMID: 32342318
- Effect of Selank on Morphological Parameters of Rat Liver in Chronic Foot-Shock Stress — Bull Exp Biol Med, 2019. PMID: 31243679
Semax in the indexed record
Indexed output for Semax stands at 207 records, a moderate literature with no registered studies currently listed on ClinicalTrials.gov.
Journals represented in the current index include ACS Chem Neurosci, Bioinorg Chem Appl, Br J Pharmacol, spanning 2020–2026.
- Semax peptide targets the μ opioid receptor gene Oprm1 to promote deubiquitination and functional recovery after spinal cord injury in female mice — Br J Pharmacol, 2025. PMID: 40692165
- Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions — J Am Acad Orthop Surg Glob Res Rev, 2026. PMID: 41490200
- Functional Connectomic Approach to Studying Selank and Semax Effects — Dokl Biol Sci, 2020. PMID: 32342318
- Semax, synthetic ACTH(4-10) analogue, attenuates behavioural and neurochemical alterations following early-life fluvoxamine exposure in white rats — Neuropeptides, 2021. PMID: 33418449
How the literature differs
The indexed record is not symmetrical between these two compounds. Semax carries 139 more indexed records than Selank, which means published methodology, characterisation data and replication attempts are more readily located for Semax. For a researcher planning a literature review, that asymmetry usually determines which compound has established reference protocols and which requires primary-source work.
Registered study counts (10 vs 0) track a different signal — formal study registration rather than published output — and the two figures frequently diverge.
Side-by-side research profile
| Parameter | Selank | Semax |
|---|---|---|
| PubMed indexed records | 68 | 207 |
| Registered studies (ClinicalTrials.gov) | 10 | 0 |
| Literature depth | Moderate | Moderate |
| Handling class | Lyophilised powder | Lyophilised powder |
| Designation | Research use only | Research use only |
Classification and why it matters
Selank and Semax sit in different structural classes, and that classification is what determines whether a published protocol for one has any bearing on the other. Peptide research compounds are grouped by sequence length, origin and the receptor families the literature associates with them — not by the outcome a reader might be looking for.
Reading across classes is the most common error in a literature review. A protocol developed for Selank describes conditions validated for Selank: concentration ranges, solvent choice, incubation windows and control selection were all established against that compound. Applying those same conditions to Semax without re-validation produces data that cannot be compared back to the source publication.
Where the two compounds are studied in overlapping models, the published work almost always treats them as separate arms rather than as substitutes. That separation is the useful signal: it indicates the research record does not consider them equivalent.
Selecting between them for a study design
Selank and Semax are not interchangeable. They differ in structural class and in the pathways the literature associates with each, so substituting one for the other changes what a model is actually measuring.
Where a protocol cites a specific compound, the cited compound is the one the published result applies to. Where no protocol exists, the compound with the deeper indexed record (Semax) generally offers more methodological precedent.
What the paperwork has to show
A certificate of analysis is only meaningful when it names the lot printed on the vial. Purity by HPLC and identity by mass spectrometry answer two different questions, and a document reporting one is not evidence of the other.
Frequently asked questions
Are Selank and Semax the same compound?
No. They are structurally distinct research compounds with separate literature records — 68 indexed records for Selank and 207 for Semax.
How should these compounds be stored?
Lyophilised material is conventionally stored at -20°C protected from light. Reconstituted solution is far less stable and is held at 2-8°C for short-duration laboratory work only.
Which of Selank or Semax has more published research?
Semax, with 207 indexed PubMed records against 68.
What is the regulatory status of these compounds?
Neither is an approved drug. Both are supplied strictly for in-vitro laboratory research and are not intended for human or veterinary consumption.
Related references
- Selank — product and lot documentation
- Semax — product and lot documentation
- Certificate of analysis & purity testing
- Research reference index
Research use only. The compounds discussed are supplied for in-vitro laboratory research. They are not drugs, are not approved for the diagnosis, treatment, cure or prevention of any condition, and are not intended for human or veterinary consumption.